NCT05085561Phase 2Completed

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Study sponsor: Recursion Pharmaceuticals Inc. · RXRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06-30Actual
Enrollment · participants62Actual
Source updated2026-10-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence and severity of adverse events (AEs) Time frame: Up to 24 months. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: A TEAE was the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. TEAES which include treatment related TEAEs, serious TEAEs, treatment-related serious TEAEs, TEAEs leading to treatment discontinuation, and treatment-related TEAEs leading to treatment discontinuation are reported. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section Time frame: Up to a maximum of 1201 days.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview